Lignin, a heterogeneous aromatic polymer present in plant biomass, is intertwined with cellulose and hemicellulose fibrils, posing challenges to its effective utilization due to its phenolic nature and recalcitrance to degradation. In this study, three lignin utilizing bacteria, Klebsiella sp. LEA1, Pseudomonas sp. LEA2, and Burkholderia sp. LEA3, were isolated from deciduous forest soil samples in Nan province, Thailand. These isolates were capable of growing on alkali lignin and various lignin-associated monomers at 40 °C under microaerobic conditions. The presence of Cu2+ significantly enhanced guaiacol oxidation in Klebsiella sp. LEA1 and Pseudomonas sp. LEA2. Lignin-related monomers and intermediates such as 2,6-dimethoxyphenol, 4-vinyl guaiacol, 4-hydroxybenzoic acid, benzoic acid, catechol, and succinic acid were detected mostly during the late stage of incubation of Klebsiella sp. LEA1 and Pseudomonas sp. LEA2 in lignin minimal salt media via GC–MS analysis. The intermediates identified from Klebsiella sp. LEA1 degradation suggested that conversion and utilization occurred through the β-ketoadipate (ortho-cleavage) pathway under limited oxygen conditions. The ability of these bacteria to thrive on alkaline lignin and produce various lignin-related intermediates under limited oxygen conditions suggests their potential utility in oxygen-limited processes and the production of renewable chemicals from plant biomass.
In recent decades, the incidence of Clostridioides difficile infection (CDI) has remained high in both community and health-care settings. With the increasing rate of treatment failures and its ability to form spores, an alternative treatment for CDI has become a global priority. We used the microdilution assay to determine minimal inhibitory concentrations (MICs) of vancomycin and teicoplanin against 30 distinct C. difficile strains isolated from various host origins. We also examined the effect of drugs on spore germination and outgrowth by following the development of OD600. Finally, we confirmed the spore germination and cell stages by microscopy. We showed that teicoplanin exhibited lower MICs compared to vancomycin in all tested isolates. MICs of teicoplanin ranged from 0.03–0.25 µg/mL, while vancomycin ranged from 0.5–4 µg/mL. Exposure of C. difficile spores to broth supplemented with various concentrations of antimicrobial agents did not affect the initiation of germination, but the outgrowth to vegetative cells was inhibited by all test compounds. This finding was concordant with aberrant vegetative cells after antibiotic treatment observed by light microscopy. This work highlights the efficiency of teicoplanin for treatment of C. difficile through prevention of vegetative cell outgrowth.
Clostridioides difficile has been recognized as a life-threatening pathogen that causes enteric diseases, including antibiotic-associated diarrhea and pseudomembranous colitis. The severity of C. difficile infection (CDI) correlates with toxin production and antibiotic resistance of C. difficile. In Thailand, the data addressing ribotypes, toxigenic, and antimicrobial susceptibility profiles of this pathogen are scarce and some of these data sets are limited. In this study, two groups of C. difficile isolates in Thailand, including 50 isolates collected from 2006 to 2009 (THA group) and 26 isolates collected from 2010 to 2012 (THB group), were compared for toxin genes and ribotyping profiles. The production of toxins A and B were determined on the basis of toxin gene profiles. In addition, minimum inhibitory concentration of eight antibiotics were examined for all 76 C. difficile isolates. The isolates of the THA group were categorized into 27 A−B+CDT− (54%) and 23 A-B-CDT- (46%), while the THB isolates were classified into five toxigenic profiles, including six A+B+CDT+ (23%), two A+B+CDT− (8%), five A−B+CDT+ (19%), seven A−B+CDT− (27%), and six A−B−CDT− (23%). By visually comparing them to the references, only five ribotypes were identified among THA isolates, while 15 ribotypes were identified within THB isolates. Ribotype 017 was the most common in both groups. Interestingly, 18 unknown ribotyping patterns were identified. Among eight tcdA-positive isolates, three isolates showed significantly greater levels of toxin A than the reference strain. The levels of toxin B in 3 of 47 tcdB-positive isolates were significantly higher than that of the reference strain. Based on the antimicrobial susceptibility test, metronidazole showed potent efficiency against most isolates in both groups. However, high MIC values of cefoxitin (MICs 256 μg/mL) and chloramphenicol (MICs ≥ 64 μg/mL) were observed with most of the isolates. The other five antibiotics exhibited diverse MIC values among two groups of isolates. This work provides evidence of temporal changes in both C. difficile strains and patterns of antimicrobial resistance in Thailand.
Salmonellosis and shigellosis remain major global health concerns, with Salmonella Typhimurium and Shigella flexneri classified as high-priority antibiotic-resistant pathogens by the World Health Organization. The development of new antibiotics is slow and challenging, underscoring the need for alternative therapeutic strategies. One promising approach involves leveraging gut microbiota-derived bacteria that confer colonization resistance against enteric pathogens. In this study, we screened a human gut microbiota culture collection and identified Bifidobacterium longum as the most effective species in inhibiting S . Typhimurium and S. flexneri in vitro . To evaluate its protective potential in vivo , we utilized Caenorhabditis elegans as a model system. Our findings demonstrate that B. longum significantly reduced pathogen burden and enhanced host survival following infection. Mechanistic analysis revealed that B. longum inhibits S . Typhimurium primarily through acidification, while S. flexneri suppression appears to involve a protein-mediated or heat-stable metabolite-dependent mechanism. Additionally, B. longum modulated host immune pathways, downregulating genes associated with the p38 MAPK and insulin/IGF-1 signaling pathways. These results highlight the potential of B. longum as a non-antibiotic therapeutic for controlling Salmonella and Shigella infections. However, further validation in mammalian models is required to assess its clinical relevance. IMPORTANCE: Gut infections caused by Salmonella and Shigella are major global health threats. As an alternative to novel drug discovery, which is time-consuming and faces several challenges, this study explores the potential of gut bacteria to protect against these pathogens. We identified Bifidobacterium longum , a common gut microbe, which can significantly reduce infection by both Salmonella and Shigella in a lab setting and in a simple animal model. The bacterium functions by creating an environment that is hostile to pathogens and by modulating the host’s immune responses. These findings suggest that B. longum could be developed as a natural, non-antibiotic treatment to control or reduce these enteric pathogen infections. This approach opens the door to using probiotics as effective tools in the global fight against antibiotic resistance.
26 March 2025 in Journal of Agriculture and Food Research